Bausch Health Companies Inc. (BHC)
NYSE: BHC · Real-Time Price · USD
7.17
+0.17 (2.43%)
At close: Aug 13, 2025, 4:00 PM
7.45
+0.28 (3.91%)
Pre-market: Aug 14, 2025, 9:07 AM EDT
Bausch Health Companies Revenue
Bausch Health Companies had revenue of $2.53B in the quarter ending June 30, 2025, with 5.29% growth. This brings the company's revenue in the last twelve months to $9.86B, up 7.13% year-over-year. In the year 2024, Bausch Health Companies had annual revenue of $9.63B with 9.91% growth.
Revenue (ttm)
$9.86B
Revenue Growth
+7.13%
P/S Ratio
0.27
Revenue / Employee
$476,232
Employees
20,700
Market Cap
2.65B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.63B | 868.00M | 9.91% |
Dec 31, 2023 | 8.76B | 633.00M | 7.79% |
Dec 31, 2022 | 8.12B | -310.00M | -3.68% |
Dec 31, 2021 | 8.43B | 407.00M | 5.07% |
Dec 31, 2020 | 8.03B | -574.00M | -6.67% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
BHC News
- 1 day ago - Why Bausch Health Stock Surged By Nearly 20% - Seeking Alpha
- 7 days ago - Bausch Health Announces 2025 Gastrointestinal Health Scholars Program Winners - Accesswire
- 14 days ago - Bausch Health Companies Inc. (BHC) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Bausch Health Announces Second Quarter 2025 Results - Accesswire
- 15 days ago - Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout - Benzinga
- 16 days ago - Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease - Accesswire
- 16 days ago - Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops - Business Wire
- 17 days ago - Bausch Health to Reduce Debt by Approximately $900 Million Using Cash On Hand - Accesswire